Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Benjamin Scirica MD

Benjamin Morgan Scirica MD

Senior Physician and Director, Innovation, Cardiovascular Division, Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School; Senior Investigator, TIMI Study Group, Boston, Massachusetts

Dr. Benjamin Scirica is a senior physician and Director of Innovation in the Cardiovascular Division at Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School. He is a Senior Investigator at the TIMI Study Group (an academic research organization based at Brigham and Women's Hospital that has performed over 75 clinical trials in cardiometabolic diseases).

His research interests center on the risk stratification, management, and the identifation of novel therapies to improve outcomes in patients with acute coronary syndromes and cardiometabolic disorders. 

Dr. Scirica has authored or co-authored over 200 peer-reviewed articles and is a reviewer for multiple journals, including The New England Journal of Medicine, JAMA, The Lancet, Circulation, and Journal of the American College of Cardiology (JACC).

Disclosures

  • Institutional research support to Brigham and Women’s Hospital from: Amgen; Better Therapeutics; Boehringer Ingelheim; Merck; Novo Nordisk; Pfizer; Verve Therapeutics
  • Consulting fees from: AbbVie (DSMB); Amgen; AstraZeneca (DSMB); Bayer; Boehringer Ingelheim (DSMB); Elsevier Practice Update Cardiology; Hanmi (DSMB); Lexeo (DSMB); Novo Nordisk; Verve Therapeutics; and equity in Health [at] Scale; Arboretum Lifescience

Recent Contributions to PracticeUpdate:

  1. Final Note From the Cardiology Board
  2. Twofold More Cardiovascular Disease Events Decades Before Type 2 Diabetes Diagnosis
  3. 2024 Top Story in Cardiology: GLP1RA, the “It” Drug Class
  4. The Effect of Semaglutide on Mortality and COVID-19–Related Deaths
  5. A Remote Management Program Improves the Utilization of GDMT in Patients With Type 2 Diabetes at High Cardiovascular and/or Kidney Risk
  6. 2023 Top Story in Cardiology: Obesity and Cardiovascular Risk—The SELECT Trial
  7. Semaglutide and Cardiovascular Outcomes in Patients With Obesity Without Diabetes
  8. Mild Hypercapnia or Normocapnia After Out-of-Hospital Cardiac Arrest
  9. Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes
  10. Comparing Ambulatory Decision-Support Tools for Heart Failure Care

Most Read This Week

Recently Updated